Article Information
History
- May 18, 2020.
Article Versions
- You are currently viewing Version 1 of this article (May 18, 2020 - 10:19).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Etienne Brochot1,2,*,
- Baptiste Demey1,2,
- Antoine Touzé3,
- Sandrine Belouzard4,
- Jean Dubuisson4,
- Jean-Luc Schmit1,2,
- Gilles Duverlie1,2,
- Catherine Francois1,2,
- Sandrine Castelain1,2 and
- Francois Helle2,*
- 1Department of Virology, Amiens University Medical Center, Amiens, France
- 2AGIR Research Unit, UR UPJV 4294, Jules Verne University of Picardie, Amiens, France
- 3ISP1282 INRA University of Tours, Tours, France
- 4Université Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019-UMR 8204-CIIL-Center for Infection and Immunity of Lille, F-59000 Lille, France
- ↵*Corresponding authors: Dr Etienne Brochot, Laboratoire de Virologie, Centre de Biologie Humaine - CHU Amiens, F-80054 Amiens cedex 1, France, Phone: +33-322-080-764, Fax: +33-322-087-009, E-mail: etienne.brochot{at}u-picardie.fr, Dr Francois Helle, UR-UPJV 4294, Agents Infectieux, Résistance et Chimiothérapie, Centre Universitaire de Recherche en Santé, 30 Avenue de la Croix Jourdain, 80000 Amiens, France, Phone: +33-322-825-351, E-mail: francois.helle{at}u-picardie.fr
Posted May 18, 2020.
Anti-Spike, anti-Nucleocapsid and neutralizing antibodies in SARS-CoV-2 hospitalized patients and asymptomatic carriers
